Lancet. 2018 Dec 19. pii: S0140-6736(18)31647-7. doi: 10.1016/S0140-6736(18)31647-7. [Epub ahead of print]
Mortality and burden of disease attributable to selected major risks
May 17,2022 MEDBOX Issue Brief no.21
Discussion Paper "Mental health, poverty and development", July 2009
Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment?
The WHO mhGAP programme’s existing guidelines recommend that either structured brief psychological treatm...ents (e.g., interpersonal psychotherapy or cognitive behavioural therapy, including behavioural activation) or antidepressant medication (e.g., SSRIsi and tricyclic antidepressants) be considered in adults with moderate-severe depression. Health care workers need to know whether these treatments have different effects, including side-effects, in treating depressive disorder in the short and long term, in order to improve clinical decision-making.
more
Q7: For people with dementia, who should be told of the diagnosis and how should the diagnosis be delivered?
Internal displacement at all-time high after unprecedented year of crises
The total number of people living in internal displacement reached a record 55 million by the end of 2020. During a year marked by intense storms and persistent conflict, 40.5 million new displacements were triggered across... the world by disasters and violence, the highest annual figure recorded in a decade.
more
WHO South-East Asia Journal of Public Health, April 2017, 6(1) 8 pp. 211 kB
Lancet Glob Health 2019Published OnlineOctober 22, 2019 https://doi.org/10.1016/S2214-109X(19)30425-5
Q8.SCOPING QUESTION: In adults and older adolescents with depressive disorder, what is the comparative effectiveness of different formats of psychological treatments?
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?